MIS-C - HAN
Coronavirus Disease 2019 (COVID-19)
This document aims to ensure that clinicians are aware of current guidance regarding Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with Coronavirus Disease 2019 (COVID-19), including the case definition and guidance on reporting to local health departments.
- Clinicians in the United Kingdom, New York City and New York State have reported cases of children with multisystem inflammatory syndrome (many of whom tested positive for SARSCoV-2 infection by RT-PCR or serologic assay). Additional reports of children presenting with severe inflammatory syndrome with a laboratory-confirmed case of COVID-19 or an epidemiological link to a COVID-19 case have been reported by authorities in other countries.
- On May 14, 2020, the Centers for Disease Control (CDC) issued a Health Advisory regarding a multisystem inflammatory syndrome in children (MIS-C) associated with coronavirus disease 2019 (COVID-19), along with a case definition for this syndrome.
- There is limited information currently available regarding the risk factors, pathogenesis, clinical course, and treatment for MIS-C.
- All health care providers should maintain a high index of suspicion for MIS-C.
- Suspected cases of MIS-C should be referred immediately to a tertiary care center with a pediatric intensive care unit (PICU).
- Tertiary care centers are asked to consider a collaborative approach in the management of these patients by convening a multispecialty committee (comprised of pediatric critical care, cardiology, hematology, infectious disease, and rheumatology/immunology) that provides coordinated clinical care guidance for each patient while (1) confirming patients meet the case definition, and (2) ensuring that appropriate diagnostic and treatment resources are readily available for this patient population.
- Hospital infection preventionists should be notified immediately upon recognition of patients meeting case definition to initiate public health reporting.
- In suspected cases of MIS-C, strongly recommend the following additional laboratory testing due to the potential for myocardial involvement: BNP and Troponin.
- If the BNP and/or Troponin levels are elevated, initiate transfer to a tertiary care center with a PICU.
- Hospitals must assess for current or recent SARS-COV-2 infection by performing a combination of RT-PCR, antigen test and/or serology (as available) in patients who are under 21 years of age and present with symptoms compatible with MIS-C associated with COVID-19.
How to Report Suspect Cases of MIS-C
How to Report Suspect Cases of MIS-C
1. Case Report Form: Fill the case report form as completely as possible, scan and send by encrypted email to email@example.com. If you need support filling out the form, please email firstname.lastname@example.org and indicate a point of contact and direct phone number for our investigators to reach you to obtain appropriate medical records to submit the form to CDC. Ideally, the case report form includes information on patient discharge but notification of the supect case should occur right away.
2. I-NEDSS entry: Enter suspect MIS-C cases into the COVID-19 I-NEDSS module – subsection “Multisystem Inflammatory Syndrome”. There does not have to be a positive COVID test in order to enter into the module. It can be an epi link, COVID-like illness, or a positive molecular, antigen, or antibody test. If your lab or a commercial send out lab does not have the ability to run serologic testing, consider drawing serum and saving it prior to any treatments.
CDC Case Definition for Multisystem Inflammatory Syndrome in Children (MIS-C)
- An individual aged <21 years presenting with fever laboratory evidence of inflammation, and evidence of clinically severe illness requiring hospitalization, with multisystem (>2) organ involvement (cardiac, renal, respiratory, hematologic, gastrointestinal, dermatologic or neurological); AND
- No alternative plausible diagnoses; AND
- Positive for current or recent SARS-CoV-2 infection by RT-PCR, serology, or antigen test; or COVID-19 exposure within the 4 weeks prior to the onset of symptoms
Fever >38.0oC for >24 hours, or report of subjective fever lasting >24 hours
Including, but not limited to, one or more of the following: an elevated C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), fibrinogen, procalcitonin, d-dimer, ferritin, lactic acid dehydrogenase (LDH), or interleukin 6 (IL-6), elevated neutrophils, reduced lymphocytes and low albumin
- Some individuals may fulfill full or partial criteria for Kawasaki disease but should be reported if they meet the case definition for MIS-C
- Consider MIS-C in any pediatric death with evidence of SARS-CoV-2 infection
Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with Coronavirus Disease 2019 (COVID-19) Interim Guidance issued July 2, 2020, reissued September 15, 2020
MIS-C Illinois Clinical Pathway issued July 31, 2020
MMWR Morb Mortal Wkly Rep: COVID-19–Associated Multisystem Inflammatory Syndrome in Children — United States, March–July 2020 published August 14, 2020
MMWR Morb Mortal Wkly Rep: SARS-CoV-2–Associated Deaths Among Persons Aged <21 Years — United States, February 12–July 31, 2020 published September 15, 2020